Qubigen (@QubigenOps) header
Qubigen (@QubigenOps) profile picture
Joined May 2025
Qubigen retweeted
BIO 2026 Debrief: AI for drug discovery must be domain-specific, privacy-preserving and deployed in a way that enables organizations to retain full control of their data and intellectual property. qubigen.com/post/bio-2026-de…
2
1
2
140
Qubigen retweeted
Qubigen is pleased to share encouraging progress from its ongoing collaboration with QIMR Berghofer. linkedin.com/posts/qubigen-i…
1
1
2
129
Qubigen retweeted
Qubigen’s recent study on tailored federated AI for blood-brain-barrier permeability prediction has now been featured by Diagnostics World News in an article exploring why specialized AI systems are outperforming generic foundation models in life sciences. diagnosticsworldnews.com/new…
🤖 Made with AI
2
1
2
132
Qubigen retweeted
Qubigen is pleased to report on a research collaboration with Dr. Srinivas Viswanathan and his team at Dana-Farber Cancer Institute. The project focuses on the discovery of novel small-molecule candidates for a rare and aggressive type of kidney cancer. qubigen.com/post/qubigen-col…
2
1
3
128
Qubigen retweeted
At Qubigen, we investigated whether our AI Engine, tailored to client-specific data using our Federated AI platform, could outperform generalist models for predicting BBB permeability. qubigen.com/post/tailored-ai…
2
1
3
119
Qubigen retweeted
Qubigen is pleased to announce the launch of a new collaborative Federated AI drug design project focused on the development of novel antiviral small molecules for emerging infectious diseases. qubigen.com/post/qubigen-lau…
2
1
3
177
Qubigen retweeted
Qubigen is pleased to announce a new collaboration with Viva Biotech, a global leader in AI-enabled drug discovery, to explore failed (‘dark’) reaction data. qubigen.com/post/qubigen-ann…
1
2
1
3
356
Matthew Oristano, Strategic Advisor and Investor in Qubigen, will attend the Bio-IT World Conference & Expo 2026 in Boston, taking place May 19–21, 2026 to forge institutional partnerships across the AI-in-Pharma ecosystem. qubigen.com/post/qubigen-to-…
1
1
1
40
Qubigen retweeted
In just over twelve months, Qubigen has evolved from an innovative idea into a validated, capital-efficient drug design platform, demonstrating that secure, Federated AI can deliver real scientific progress, commercial traction, and scalable value. qubigen.com/post/one-year-of…
1
1
1
55
Qubigen retweeted
At Qubigen, we do something fundamentally different: we build AI Engines for drug design using our secure Federated AI Drug Design platform (FedAIDD). Our clients generate truly novel compounds, without their data ever leaving its server. qubigen.com/post/federated-a…
2
1
2
100
Qubigen retweeted
Qubigen's CEO, Dr Jonathan Hall, and Chief Information Officer, A/Prof Dr Jun Zeng, will be presenting at the Walter and Eliza Hall Institute of Medical Research (WEHI) Divisional Seminar Program 10:45 AM, Thursday, 20 November 2025 qubigen.com/post/qubigen-to-…
1
1
2
281
We’re excited to introduce the next group of Xtalks Featured Community Members, celebrating the people advancing life sciences across pharma, biotech, medtech, healthcare and beyond. Our newest members include: · Christopher Missling, PhD, President & CEO, Anavex Life Sciences · Jonathan Hall, PhD, Founder & CEO, Qubigen · Mark Franklin, Manager, Curation, DrugBank · Petra Elischer, Head of Quality and Regulatory Affairs, Hart Biologicals Limited · Rebecca Starkie, Consultant, Civia Health Meet them all at buff.ly/LSA0I1d and learn how to apply or nominate a colleague at buff.ly/LdsbLY7. #LifeSciences #Biotech #Pharma #MedTech #ClinicalResearch #XtalksCommunity #Leadership
2
1
3
453
Qubigen retweeted
Qubigen is pleased to announce that Matthew Oristano, Strategic Advisor and Investor in Qubigen, will be attending Discovery on Target (DOT) 2025 in Boston, taking place on September 22nd–25th, 2025. qubigen.com/post/qubigen-to-…
1
1
2
163
Qubigen retweeted
Qubigen Signs Data Access Agreement with Flinders University, enabling Qubigen to apply its Federated AI platform and proprietary quantum chemistry-based drug design technologies to research programs in partnership with Flinders University. qubigen.com/post/qubigen-sig…
1
1
3
79